NO2010017I2 - Eltrombopag olamine - Google Patents

Eltrombopag olamine

Info

Publication number: NO2010017I2
Authority: NO; Norway
Prior art keywords: eltrombopag olamine; eltrombopag; olamine
Prior art date: 2000-05-25

Application number

NO2010017C

Other languages

English (en)

Other versions

NO2010017I1 (no

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-25

Filing date

2010-08-19

Publication date

2012-06-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2010017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-19 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2010-09-20 Publication of NO2010017I1 publication Critical patent/NO2010017I1/no

2012-06-11 Publication of NO2010017I2 publication Critical patent/NO2010017I2/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pyridine Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Information Transfer Systems (AREA)
Vehicle Body Suspensions (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Hard Magnetic Materials (AREA)

NO2010017C 2000-05-25 2010-08-19 Eltrombopag olamine NO2010017I2 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20708400P	2000-05-25	2000-05-25
US22892900P	2000-08-30	2000-08-30
PCT/US2001/016863 WO2001089457A2 (en)	2000-05-25	2001-05-24	Thrombopoietin mimetics

Publications (2)

Publication Number	Publication Date
NO2010017I1 NO2010017I1 (no)	2010-09-20
NO2010017I2 true NO2010017I2 (no)	2012-06-11

Family

ID=26901947

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20025566A NO324246B1 (no)	2000-05-25	2002-11-20	Trombopoietin-etterlignere
NO2010017C NO2010017I2 (no)	2000-05-25	2010-08-19	Eltrombopag olamine
NO2020040C NO2020040I1 (no)	2000-05-25	2020-11-19	eltrombopag olamine - Forlenget SPC

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20025566A NO324246B1 (no)	2000-05-25	2002-11-20	Trombopoietin-etterlignere

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2020040C NO2020040I1 (no)	2000-05-25	2020-11-19	eltrombopag olamine - Forlenget SPC

Country Status (30)

Country	Link
US (9)	US7160870B2 (no)
EP (3)	EP1864981B8 (no)
JP (2)	JP3813875B2 (no)
KR (2)	KR100798568B1 (no)
CN (4)	CN101343250B (no)
AR (2)	AR030696A1 (no)
AT (2)	ATE374772T1 (no)
AU (2)	AU7493801A (no)
BE (1)	BE2010C018I2 (no)
BR (1)	BRPI0111116B8 (no)
CA (1)	CA2411468C (no)
CY (4)	CY2010012I2 (no)
CZ (1)	CZ303176B6 (no)
DE (4)	DE122010000037I1 (no)
DK (3)	DK1294378T3 (no)
ES (3)	ES2294000T3 (no)
FR (1)	FR10C0034I2 (no)
HK (1)	HK1056114A1 (no)
HU (3)	HU230387B1 (no)
IL (5)	IL152988A0 (no)
LU (1)	LU91681I2 (no)
MX (1)	MXPA02011621A (no)
MY (1)	MY136707A (no)
NO (3)	NO324246B1 (no)
NZ (2)	NZ522474A (no)
PL (2)	PL216528B1 (no)
PT (3)	PT1294378E (no)
SI (3)	SI1889838T1 (no)
TW (1)	TWI305207B (no)
WO (1)	WO2001089457A2 (no)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003525944A (ja)	2000-03-08	2003-09-02	メタバシス・セラピューティクス・インコーポレイテッド	新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
US20110212054A1 (en) *	2000-05-25	2011-09-01	Glaxosmithkline Llc.	Thrombopoietin mimetics
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
EP1370252A4 (en) *	2001-03-01	2006-04-05	Smithkline Beecham Corp	Thrombopoietin mimetics
US7659409B2 (en)	2002-03-19	2010-02-09	Mitsubishi Chemical Corporation	3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
MY142390A (en) *	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en) *	2002-06-06	2003-12-18	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1552828A4 (en)	2002-08-14	2007-01-24	Nissan Chemical Ind Ltd	THROMBOPOIETIN RECEPTOR ACTIVATOR AND METHOD OF PRODUCTION
TWI324593B (en)	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
EP1622609A4 (en) *	2003-04-29	2008-09-03	Smithkline Beecham Corp	METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
US20090048318A1 (en) *	2003-04-29	2009-02-19	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US20100004302A1 (en) *	2003-04-29	2010-01-07	Connie Erickson-Miller	Methods for Treating Degenerative Diseases/Injuries
US20090143453A1 (en) *	2003-04-29	2009-06-04	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US7753958B2 (en) *	2003-08-05	2010-07-13	Gordon Charles R	Expandable intervertebral implant
SE0302486D0 (sv) *	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
TW200526638A (en) *	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en)	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Thrombopoietin activity modulating compounds and methods
CA2581454A1 (en) *	2004-09-23	2006-03-30	Reddy Us Therapeutics, Inc.	Novel pyrimidine compounds, process for their preparation and compositions containing them
CA2583764C (en)	2004-10-25	2009-06-09	Ligand Pharmaceuticals, Inc.	Thrombopoietin activity modulating compounds and methods
CA2588979C (en)	2004-12-08	2013-01-22	Nissan Chemical Industries, Ltd.	3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
US8134013B2 (en)	2004-12-14	2012-03-13	Nissan Chemical Industries, Ltd.	Amide compound and thrombopoietin receptor activator
PE20070083A1 (es)	2005-06-08	2007-01-27	Smithkline Beecham Corp	(5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
WO2007010954A1 (en)	2005-07-15	2007-01-25	Nissan Chemical Industries, Ltd.	Thiophene compounds and thrombopoietin receptor activators
KR101290484B1 (ko)	2005-07-20	2013-07-26	닛산 가가쿠 고교 가부시키 가이샤	피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
JP2009511603A (ja) *	2005-10-13	2009-03-19	スミスクライン・ビーチャム・コーポレイション	貯蔵中の血小板の有効性を維持する方法
JP5205967B2 (ja)	2005-11-07	2013-06-05	日産化学工業株式会社	ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
JP5157900B2 (ja)	2006-06-07	2013-03-06	日産化学工業株式会社	含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
CA2670345A1 (en) *	2006-12-01	2008-06-12	Stategics, Inc.	Thrombopoietin mimetics
US20110129550A1 (en) *	2007-02-16	2011-06-02	Connie Erickson-Miller	Cancer treatment method
US20110160130A1 (en) *	2007-02-16	2011-06-30	Connie Erickson-Miller	Cancer treatment method
UY30915A1 (es) *	2007-02-16	2008-09-02	Smithkline Beecham Corp	Método de tratamiento de canceres
WO2008134338A1 (en) *	2007-04-24	2008-11-06	Smithkline Beecham Corporation	Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
EA022915B1 (ru) *	2007-10-09	2016-03-31	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
CN101481352A (zh) *	2008-01-10	2009-07-15	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US8236838B2 (en)	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en)	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
WO2009151862A1 (en) *	2008-05-15	2009-12-17	Smithkline Beecham Corporation	Method of treatment
WO2010045310A1 (en) *	2008-10-16	2010-04-22	Glaxosmithkline Llc	Method of treating thrombocytopenia
PE20100362A1 (es)	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
TWI379681B (en) *	2009-04-01	2012-12-21	Pliva Hrvatska D O O	Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
US8476249B2 (en)	2009-05-07	2013-07-02	Glaxosmithkline Llc	Method of treating thrombocytopenia
WO2010129738A1 (en) *	2009-05-07	2010-11-11	Glaxosmithkline Llc	Method of treating thrombocytopenia
US8680150B2 (en) *	2009-05-28	2014-03-25	Ligand Pharmaceuticals, Inc.	Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
SG176088A1 (en) *	2009-05-29	2011-12-29	Glaxosmithkline Llc	Methods of administration of thrombopoietin agonist compounds
CN101921232A (zh) *	2009-06-11	2010-12-22	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
CN102639314B (zh)	2009-12-01	2015-04-29	巴斯夫欧洲公司	基于聚氨酯的拉挤成型树脂体系
CN101805291A (zh) *	2010-04-26	2010-08-18	西北大学	1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
BR112013004714A2 (pt)	2010-09-01	2016-05-17	Novartis Ag	"combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
WO2012102937A2 (en)	2011-01-25	2012-08-02	Irm Llc	Compounds that expand hematopoietic stem cells
WO2012121958A2 (en) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Combination
WO2012121957A1 (en) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Combination
US20120309796A1 (en)	2011-06-06	2012-12-06	Fariborz Firooznia	Benzocycloheptene acetic acids
WO2013006806A1 (en) *	2011-07-06	2013-01-10	Cellerant Therapeutics, Inc.	Megakaryocyte progenitor cells for production of platelets
SI2750677T1 (sl) *	2011-08-30	2017-10-30	Chdi Foundation, Inc.	Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
US9440927B2 (en)	2011-09-13	2016-09-13	Glenmark Pharmaceuticals Limited	Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds
WO2013049605A1 (en)	2011-09-28	2013-04-04	Assia Chemical Industries Ltd.	Processes for the preparation of an intermediate in the synthesis of eltrombopag
CA2851788C (en)	2011-10-11	2022-11-29	Dana-Farber Cancer Institute, Inc.	Pyrazol-3-ones that activate pro-apoptotic bax
WO2013074459A1 (en)	2011-11-14	2013-05-23	Ligand Pharmaceuticals, Inc.	Methods and compositions associated with the granulocyte colony-stimulating factor receptor
EP2788476B1 (en)	2011-12-08	2019-05-22	Fred Hutchinson Cancer Research Center	Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
EP2807165B1 (en)	2012-01-27	2019-05-15	Université de Montréal	Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
CN103360317B (zh) *	2012-04-11	2016-12-14	齐鲁制药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) *	2012-05-22	2015-08-27	国立大学法人旭川医科大学	ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) *	2012-08-13	2014-02-13	University Of Rochester	Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
US9962370B2 (en)	2013-03-15	2018-05-08	Ligand Pharmaceuticals Incorporated	Methods of treatment associated with the granulocyte colony-stimulating factor receptor
EP2799425A1 (en)	2013-04-29	2014-11-05	Esteve Química, S.A.	Preparation process of an agonist of the thrombopoietin receptor
WO2015029074A2 (en)	2013-09-02	2015-03-05	Hetero Research Foundation	Compositions of eltrombopag
ITMI20131782A1 (it) *	2013-10-25	2015-04-26	Dipharma Francis Srl	Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) *	2013-11-12	2015-05-20	上海医药工业研究院	3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	一种爱曲伯帕的合成方法
WO2015111085A2 (en)	2014-01-27	2015-07-30	Cadila Healthcare Limited	Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN103819406B (zh) *	2014-03-17	2015-04-08	苏州明锐医药科技有限公司	艾曲波帕的制备方法
JP6762233B2 (ja)	2014-04-22	2020-09-30	ウニヴェルシテドモントリオールＵｎｉｖｅｒｓｉｔｅＤｅＭｏｎｔｒｅａｌ	化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
CN105085287A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
CN105085276A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	艾曲波帕中间体及其制备方法和应用
AU2015289492B2 (en)	2014-07-17	2020-02-20	Chdi Foundation, Inc.	Methods and compositions for treating HIV-related disorders
US10336706B2 (en)	2014-09-05	2019-07-02	Hetero Research Foundation	Crystalline form of Eltrombopag free acid
WO2016055935A1 (en)	2014-10-06	2016-04-14	Glaxosmithkline Intellectual Property (No.2) Limited	Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
JP6658535B2 (ja)	2014-10-31	2020-03-04	日産化学株式会社	リガンド結合繊維及び当該繊維を用いた細胞培養基材
CN104829593B (zh) *	2015-03-26	2017-08-25	苏州福来兹检测科技有限公司	一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (en)	2015-09-08	2017-03-16	Actavis Group Ptc Ehf.	Novel eltrombopag salt and preparation thereof
CA3021103A1 (en)	2016-04-21	2017-10-26	Basf Se	Method for producing pultruded products on the basis of polyurethane
JP7104636B2 (ja)	2016-06-27	2022-07-21	ザジェネラルホスピタルコーポレーションドゥーイングビジネスアズマサチューセッツジェネラルホスピタル	ミトコンドリア生物の活性化による血小板産生刺激
CN110382580B (zh)	2017-03-09	2022-04-19	巴斯夫欧洲公司	制备复合元件的聚氨酯制剂
CN107021928B (zh) *	2017-04-01	2022-11-18	常州制药厂有限公司	艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (en)	2017-04-26	2019-08-21	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical tablet composition comprising eltrombopag olamine
WO2019071111A1 (en)	2017-10-06	2019-04-11	Teva Pharmaceuticals Usa, Inc.	FORMS IN THE STRONG STATE OF ELTROMBOPAG CHOLINE
EP3409272B1 (en)	2018-03-07	2020-06-24	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
CN110467531B (zh) *	2018-05-09	2022-04-19	新发药业有限公司	一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
WO2019229572A1 (en) *	2018-06-01	2019-12-05	Aurobindo Pharma Ltd	An improved process for the preparation of eltrombopag olamine and its intermediates
EP3604285B1 (en)	2018-08-02	2020-06-17	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Highly stable crystalline form d1 of the eltrombopag monoethanolamine salt
EP3604284B1 (en)	2018-08-02	2020-11-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Crystalline eltrombopag monoethanolamine salt form d
EP3909645A4 (en) *	2019-01-08	2022-07-27	Jiangsu Hengrui Medicine Co., Ltd.	DOSING REGIME FOR A BICYCLIC SUBSTITUTE PYRAZOLONEAZOLE DERIVATIVE
WO2021001044A1 (en)	2019-07-04	2021-01-07	F.I.S. - Fabbrica Italiana Sintetici S.P.A.	Process for the preparation of key intermediates for the synthesis of eltrombopag or salt thereof
JP7083793B2 (ja) *	2019-09-10	2022-06-13	Ｊｆｅケミカル株式会社	パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
WO2021055820A1 (en)	2019-09-20	2021-03-25	Novartis Ag	3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN114341113A (zh) *	2019-10-21	2022-04-12	广东东阳光药业有限公司	乙酰化艾曲波帕的新晶型及其制备方法
WO2021078076A1 (zh) *	2019-10-21	2021-04-29	广东东阳光药业有限公司	乙酰化艾曲波帕的新晶型及其制备方法
EP4069203A1 (en)	2019-12-06	2022-10-12	Synthon B.V.	Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
CA3160779A1 (en)	2019-12-06	2021-06-10	Synthon B.V.	Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
TR202014694A1 (tr)	2020-09-16	2022-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (en)	2021-03-25	2022-09-29	Novartis Ag	3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN113336704B (zh) *	2021-06-11	2022-10-11	上海大学	丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) *	2021-12-02	2022-05-17	天津力生制药股份有限公司	一种艾曲波帕的制备方法
WO2023111187A1 (en)	2021-12-15	2023-06-22	Galenicum Health, S.L.U	Pharmaceutical compositions comprising eltrombopag
CN116354885A (zh) *	2021-12-27	2023-06-30	苏州特瑞药业股份有限公司	一种艾曲波帕新晶型及其制备方法
WO2025140275A1 (zh) *	2023-12-25	2025-07-03	江苏恒瑞医药股份有限公司	取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE193350C (no)
US851444A (en)	1905-11-13	1907-04-23	Agfa Ag	Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en)	1953-02-27	1957-07-24	Ciba Ltd	Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) *	1954-10-26	1957-10-15	Ciba Ltd	Azo-dyestuffs
DE1046220B (de) *	1956-04-21	1958-12-11	Bayer Ag	Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en)	1956-07-23	1959-12-31	Bayer Ag	ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en)	1956-11-20	1960-08-23	Agfa Ag	Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en)	1965-04-09	1968-01-30	Interchem Corp	Disazo pyrazolone pigments
US4435417A (en)	1981-02-20	1984-03-06	Gruppo Lepetit S.P.A.	Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES8503669A1 (es)	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) *	1984-02-10	1986-12-05	Sandoz Sa	Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi)	1987-03-18	1994-08-25	Tanabe Seiyaku Co	Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en)	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
US5326776A (en)	1992-03-02	1994-07-05	Abbott Laboratories	Angiotensin II receptor antagonists
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de)	1993-08-13	1995-02-15	Ciba-Geigy Ag	Pigmentsalze
EP0661170B1 (en)	1993-12-28	1998-09-02	Dai Nippon Printing Co., Ltd.	Thermal transfer sheet
GB2285446B (en) *	1994-01-03	1999-07-28	Genentech Inc	Thrombopoietin
NZ271230A (en)	1994-02-14	1998-03-25	Zymogenetics Inc	Hematopoietic proteins, production and use
US5482546A (en)	1994-03-30	1996-01-09	Canon Kabushiki Kaisha	Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en)	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en)	1995-02-13	1998-05-05	Engelhard Corporation	Pigment compositions
US6083913A (en)	1995-06-07	2000-07-04	Glaxo Wellcome Inc.	Peptides and compounds that bind to a thrombopoietin receptor
US5622818A (en)	1995-11-29	1997-04-22	Eastman Kodak Company	Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en)	1996-05-30	1997-09-23	Engelhard Corporation	Pigment compositions
US5932546A (en)	1996-10-04	1999-08-03	Glaxo Wellcome Inc.	Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
GB9715830D0 (en)	1997-07-25	1997-10-01	Basf Ag	Reactive dyes containing piperazine
WO1999011262A1 (en)	1997-09-02	1999-03-11	Roche Diagnostics Gmbh	Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
US6280959B1 (en)	1997-10-31	2001-08-28	Smithkline Beecham Corporation	Metal complexes
DE19851389A1 (de)	1998-11-07	2000-05-11	Dystar Textilfarben Gmbh & Co	Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) *	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
US6750342B1 (en)	1999-05-19	2004-06-15	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
CN1376150A (zh)	1999-07-26	2002-10-23	盐野义制药株式会社	具有血栓形成素受体拮抗作用的药物组合物
AU770564B2 (en) *	1999-09-10	2004-02-26	Smithkline Beecham Corporation	Thrombopoietin mimetics
WO2001021180A1 (en) *	1999-09-24	2001-03-29	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1228051A1 (en)	1999-11-05	2002-08-07	SmithKline Beecham Corporation	Semicarbazone derivatives and their use as thrombopoietin mimetics
EP1104674A1 (de)	1999-11-10	2001-06-06	Curacyte AG	O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
TWI284639B (en)	2000-01-24	2007-08-01	Shionogi & Co	A compound having thrombopoietin receptor agonistic effect
MY133845A (en)	2000-03-10	2007-11-30	Smithkline Beecham Corp	Il-8 receptor antagonists
US6436915B1 (en)	2000-04-07	2002-08-20	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6214813B1 (en) *	2000-04-07	2001-04-10	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
CY2010012I2 (el)	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
US6642265B1 (en) *	2000-09-08	2003-11-04	Smithkline Beecham Corporation	Thrombopoietin mimetics
JP2004520302A (ja)	2000-12-19	2004-07-08	スミスクライン・ビーチャム・コーポレイション	トロンボポエチン模倣物
ATE384076T1 (de)	2000-12-21	2008-02-15	Smithkline Beecham Corp	Regulierte aktivierung von zellmembranrezeptoren durch metallchelatisierende agonisten
EP1361220A4 (en)	2001-01-26	2005-09-07	Shionogi & Co	CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
MXPA03006510A (es)	2001-01-26	2003-10-15	Shionogi & Co	Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
EP1370252A4 (en)	2001-03-01	2006-04-05	Smithkline Beecham Corp	Thrombopoietin mimetics
JP3927001B2 (ja)	2001-06-15	2007-06-06	三菱化学株式会社	色素セット、インクセット並びに記録方法
US6560161B1 (en) *	2001-08-30	2003-05-06	Micron Technology, Inc.	Synchronous flash memory command sequence
AU2002333114B2 (en)	2001-11-30	2008-09-04	Qlt Inc.	Hydrazonopyrazole derivatives and their use as therapeutics
WO2003074550A2 (en)	2002-03-01	2003-09-12	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
MY142390A (en)	2002-05-22	2010-11-30	Glaxosmithkline Llc	3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en)	2002-06-06	2003-12-18	Smithkline Beecham Corporation	Thrombopoietin mimetics
TWI324593B (en) *	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
AU2003297925A1 (en)	2002-12-13	2004-07-09	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1622609A4 (en)	2003-04-29	2008-09-03	Smithkline Beecham Corp	METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
TW200526638A (en) *	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) *	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Thrombopoietin activity modulating compounds and methods
CA2583764C (en) *	2004-10-25	2009-06-09	Ligand Pharmaceuticals, Inc.	Thrombopoietin activity modulating compounds and methods
JP2009511603A (ja) *	2005-10-13	2009-03-19	スミスクライン・ビーチャム・コーポレイション	貯蔵中の血小板の有効性を維持する方法
CA2670345A1 (en) *	2006-12-01	2008-06-12	Stategics, Inc.	Thrombopoietin mimetics

2000
- 2000-06-03 CY CY2010012C patent/CY2010012I2/el unknown
2001
- 2001-05-23 TW TW090112317A patent/TWI305207B/zh not_active IP Right Cessation
- 2001-05-23 MY MYPI20012430A patent/MY136707A/en unknown
- 2001-05-23 AR ARP010102468A patent/AR030696A1/es active IP Right Grant
- 2001-05-24 EP EP07112105A patent/EP1864981B8/en not_active Expired - Lifetime
- 2001-05-24 NZ NZ522474A patent/NZ522474A/en not_active IP Right Cessation
- 2001-05-24 ES ES01941599T patent/ES2294000T3/es not_active Expired - Lifetime
- 2001-05-24 US US10/296,688 patent/US7160870B2/en not_active Expired - Lifetime
- 2001-05-24 MX MXPA02011621A patent/MXPA02011621A/es active IP Right Grant
- 2001-05-24 PL PL359270A patent/PL216528B1/pl unknown
- 2001-05-24 CN CN200810129758XA patent/CN101343250B/zh not_active Expired - Fee Related
- 2001-05-24 EP EP07112106A patent/EP1889838B1/en not_active Expired - Lifetime
- 2001-05-24 DE DE122010000037C patent/DE122010000037I1/de active Pending
- 2001-05-24 DE DE60139354T patent/DE60139354D1/de not_active Expired - Lifetime
- 2001-05-24 KR KR1020027015869A patent/KR100798568B1/ko not_active Expired - Lifetime
- 2001-05-24 HU HU0800310A patent/HU230387B1/hu not_active IP Right Cessation
- 2001-05-24 CA CA002411468A patent/CA2411468C/en not_active Expired - Lifetime
- 2001-05-24 EP EP01941599A patent/EP1294378B1/en not_active Expired - Lifetime
- 2001-05-24 WO PCT/US2001/016863 patent/WO2001089457A2/en not_active Ceased
- 2001-05-24 BR BRPI0111116A patent/BRPI0111116B8/pt not_active IP Right Cessation
- 2001-05-24 CN CNB018133401A patent/CN100423721C/zh not_active Expired - Lifetime
- 2001-05-24 CZ CZ20023852A patent/CZ303176B6/cs not_active IP Right Cessation
- 2001-05-24 ES ES07112106T patent/ES2334843T3/es not_active Expired - Lifetime
- 2001-05-24 HU HU0302257A patent/HU227476B1/hu active Protection Beyond IP Right Term
- 2001-05-24 PT PT01941599T patent/PT1294378E/pt unknown
- 2001-05-24 AU AU7493801A patent/AU7493801A/xx active Pending
- 2001-05-24 AT AT01941599T patent/ATE374772T1/de active
- 2001-05-24 CN CN2008101297594A patent/CN101343251B/zh not_active Expired - Fee Related
- 2001-05-24 PT PT07112106T patent/PT1889838E/pt unknown
- 2001-05-24 PL PL393259A patent/PL218617B1/pl unknown
- 2001-05-24 HK HK03106754.0A patent/HK1056114A1/zh unknown
- 2001-05-24 ES ES07112105T patent/ES2328179T3/es not_active Expired - Lifetime
- 2001-05-24 IL IL15298801A patent/IL152988A0/xx active IP Right Grant
- 2001-05-24 AT AT07112106T patent/ATE445606T1/de active
- 2001-05-24 AU AU2001274938A patent/AU2001274938C1/en not_active Expired
- 2001-05-24 DE DE60140224T patent/DE60140224D1/de not_active Expired - Lifetime
- 2001-05-24 KR KR1020077018036A patent/KR100847172B1/ko not_active Expired - Fee Related
- 2001-05-24 SI SI200130955T patent/SI1889838T1/sl unknown
- 2001-05-24 DK DK01941599T patent/DK1294378T3/da active
- 2001-05-24 SI SI200130938T patent/SI1864981T1/sl unknown
- 2001-05-24 DE DE60130760T patent/DE60130760T2/de not_active Expired - Lifetime
- 2001-05-24 NZ NZ533308A patent/NZ533308A/en not_active IP Right Cessation
- 2001-05-24 SI SI200130790T patent/SI1294378T1/sl unknown
- 2001-05-24 CN CNA2008101297607A patent/CN101342169A/zh active Pending
- 2001-05-24 PT PT07112105T patent/PT1864981E/pt unknown
- 2001-05-24 JP JP2001585703A patent/JP3813875B2/ja not_active Expired - Lifetime
- 2001-05-24 DK DK07112106.5T patent/DK1889838T3/da active
- 2001-05-24 DK DK07112105T patent/DK1864981T3/da active
- 2001-05-24 HU HU0800710A patent/HU230487B1/hu not_active IP Right Cessation
2002
- 2002-11-20 NO NO20025566A patent/NO324246B1/no active Protection Beyond IP Right Term
- 2002-11-20 IL IL152988A patent/IL152988A/en active Protection Beyond IP Right Term
2005
- 2005-12-07 JP JP2005353686A patent/JP4546919B2/ja not_active Expired - Fee Related
2006
- 2006-11-09 US US11/558,071 patent/US7335649B2/en not_active Expired - Fee Related
2007
- 2007-01-05 US US11/620,260 patent/US7332481B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,688 patent/US7439342B2/en not_active Expired - Fee Related
- 2007-01-08 US US11/650,651 patent/US7473686B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,838 patent/US7452874B2/en not_active Expired - Lifetime
- 2007-12-13 CY CY20071101583T patent/CY1107087T1/el unknown
2008
- 2008-05-02 AR ARP080101867A patent/AR066036A2/es active IP Right Grant
- 2008-06-18 US US12/141,397 patent/US7790704B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,422 patent/US7648971B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,379 patent/US7674887B2/en not_active Expired - Fee Related
- 2008-08-21 IL IL193618A patent/IL193618A0/en not_active IP Right Cessation
- 2008-08-21 IL IL193617A patent/IL193617A/en not_active IP Right Cessation
- 2008-08-21 IL IL193619A patent/IL193619A0/en unknown
2009
- 2009-08-13 CY CY20091100873T patent/CY1109435T1/el unknown
2010
- 2010-01-11 CY CY20101100027T patent/CY1109730T1/el unknown
- 2010-04-13 BE BE2010C018C patent/BE2010C018I2/fr unknown
- 2010-04-21 LU LU91681C patent/LU91681I2/fr unknown
- 2010-06-18 FR FR10C0034C patent/FR10C0034I2/fr active Active
- 2010-08-19 NO NO2010017C patent/NO2010017I2/no unknown
2020
- 2020-11-19 NO NO2020040C patent/NO2020040I1/no unknown

Also Published As

Publication number	Publication date
CY1107087T1 (el)	2012-01-25
AU2001274938C1 (en)	2006-09-28
US20080090787A1 (en)	2008-04-17
CN101343250B (zh)	2011-09-21
IL193618A0 (en)	2009-02-11
WO2001089457A2 (en)	2001-11-29
ATE445606T1 (de)	2009-10-15
US20080214640A1 (en)	2008-09-04
AU2001274938B2 (en)	2006-01-19
PT1864981E (pt)	2009-08-31
US20040019190A1 (en)	2004-01-29
PT1889838E (pt)	2010-01-19
JP2006137764A (ja)	2006-06-01
HUP0302257A3 (en)	2007-03-28
HU230387B1 (hu)	2016-03-29
US7439342B2 (en)	2008-10-21
ES2328179T3 (es)	2009-11-10
US7648971B2 (en)	2010-01-19
IL152988A (en)	2009-02-11
TWI305207B (en)	2009-01-11
KR20070087255A (ko)	2007-08-27
BE2010C018I2 (no)	2020-08-20
HU230487B1 (hu)	2016-08-29
PL393259A1 (pl)	2011-07-04
MXPA02011621A (es)	2004-05-17
CN101343250A (zh)	2009-01-14
HU227476B1 (en)	2011-07-28
IL152988A0 (en)	2003-06-24
US20070179192A1 (en)	2007-08-02
US20070129338A1 (en)	2007-06-07
NO20025566L (no)	2003-01-22
IL193617A0 (en)	2009-02-11
CA2411468C (en)	2008-04-15
US7335649B2 (en)	2008-02-26
PL218617B1 (pl)	2015-01-30
US7790704B2 (en)	2010-09-07
ES2294000T3 (es)	2008-04-01
CN101343251B (zh)	2011-11-09
NZ533308A (en)	2005-10-28
SI1889838T1 (sl)	2010-02-26
JP3813875B2 (ja)	2006-08-23
DE60140224D1 (de)	2009-11-26
EP1864981B1 (en)	2009-07-22
EP1294378B1 (en)	2007-10-03
HK1056114A1 (zh)	2004-02-06
NO2020040I1 (no)	2020-11-19
AR030696A1 (es)	2003-09-03
NZ522474A (en)	2004-10-29
CY2010012I2 (el)	2020-05-29
LU91681I9 (no)	2019-01-03
KR100798568B1 (ko)	2008-01-28
LU91681I2 (fr)	2010-06-21
HK1117825A1 (en)	2009-01-23
CA2411468A1 (en)	2001-11-29
ATE374772T1 (de)	2007-10-15
CY1109435T1 (el)	2014-08-13
JP4546919B2 (ja)	2010-09-22
US20090155203A1 (en)	2009-06-18
SI1864981T1 (sl)	2009-12-31
BRPI0111116B8 (pt)	2021-05-25
EP1864981B8 (en)	2009-11-11
KR100847172B1 (ko)	2008-07-17
US7674887B2 (en)	2010-03-09
IL193619A0 (en)	2009-02-11
HUP0302257A2 (hu)	2003-10-28
US20080090996A1 (en)	2008-04-17
FR10C0034I1 (no)	2010-06-08
PL216528B1 (pl)	2014-04-30
PL359270A1 (en)	2004-08-23
DE122010000037I1 (de)	2011-01-27
HK1113057A1 (en)	2008-09-19
DE60139354D1 (de)	2009-09-03
AU7493801A (en)	2001-12-03
DK1294378T3 (da)	2008-01-28
BR0111116B1 (pt)	2013-10-08
US20090176746A1 (en)	2009-07-09
CN101343251A (zh)	2009-01-14
HU0800310D0 (en)	2008-07-28
NO2010017I1 (no)	2010-09-20
HU0800710D0 (en)	2009-01-28
PT1294378E (pt)	2008-01-09
EP1864981A1 (en)	2007-12-12
US7160870B2 (en)	2007-01-09
IL193617A (en)	2013-06-27
NO20025566D0 (no)	2002-11-20
US7452874B2 (en)	2008-11-18
FR10C0034I2 (fr)	2011-04-29
US20090176973A1 (en)	2009-07-09
HK1055561A1 (en)	2004-01-16
BR0111116A (pt)	2003-04-08
KR20030060773A (ko)	2003-07-16
DE60130760D1 (de)	2007-11-15
US7332481B2 (en)	2008-02-19
SI1294378T1 (sl)	2008-02-29
US7473686B2 (en)	2009-01-06
AR066036A2 (es)	2009-07-22
EP1889838B1 (en)	2009-10-14
ES2334843T3 (es)	2010-03-16
CZ303176B6 (cs)	2012-05-16
CN101342169A (zh)	2009-01-14
EP1889838A1 (en)	2008-02-20
CY1109730T1 (el)	2014-09-10
EP1294378A2 (en)	2003-03-26
DE60130760T2 (de)	2008-07-17
JP2003534257A (ja)	2003-11-18
WO2001089457A3 (en)	2002-03-07
CZ20023852A3 (cs)	2003-05-14
HUP0800710A2 (hu)	2003-10-28
DK1889838T3 (da)	2010-02-08
CY2010012I1 (el)	2012-01-25
MY136707A (en)	2008-11-28
CN100423721C (zh)	2008-10-08
NO324246B1 (no)	2007-09-17
EP1294378A4 (en)	2004-01-28
DK1864981T3 (da)	2009-09-07
CN1444477A (zh)	2003-09-24

Publication	Publication Date	Title
NO2010017I2 (no)	2012-06-11	Eltrombopag olamine
ATE333445T1 (de)	2006-08-15	Pyrazolderivate
DE60126286D1 (de)	2007-03-15	Substituierte pyrazole
CY1104912T1 (el)	2009-11-04	Υποκατεστημενα πυραζολια
DE60133503D1 (de)	2008-05-21	Stereomikroskop
DK1292604T3 (da)	2009-06-15	2-Aminocarbonyl-9H-purinderivater
NO20025517L (no)	2002-11-18	Triazolderivater
NO20030473L (no)	2003-01-30	Imidazolyl-derivater
ATE288437T1 (de)	2005-02-15	Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
NO20030276L (no)	2003-03-18	Fremgangsmåte
DK1571140T3 (da)	2009-03-09	Substituerede C-cyjklohexylmethylamin-derivater
ATE335740T1 (de)	2006-09-15	Ringannelierte pyrazolderivate
ATE282021T1 (de)	2004-11-15	Substituierte aminomethyl-phenyl- cyclohexanderivate
DK1322593T3 (da)	2004-10-11	O-substituerede-6-methyl-tramadol-derivater
DK1246791T3 (da)	2005-02-14	Aminomethyl-phenyl-cyklohexanonderivater
FI20001551L (fi)	2001-12-30	Saranat
DK1322590T3 (da)	2007-09-03	Substituerede 5-amino-1-penten-3-ol-derivater
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no)	2002-09-13	2-fenylpyran-4-on-derivater
FI4651U1 (fi)	2000-09-29	Kaivo
FI20001398L (fi)	2001-12-13	Kaivo
SK2571U (sk)	2000-07-11	Skladačkový dutinový segment
SE0003577D0 (sv)	2000-09-28	Double connect